A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 41 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-08-03.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 19th largest by enrollment, is one of 3 that started in 2021, is one of 19 in phase 3, and was the 14th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2021.
This study's enrollment of 69 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 120 across the 23 interventional studies. Of the 18 that completed or were terminated, 17 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 23 have an industry lead sponsor. The 4 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 63rd largest by enrollment of the 116 interventional ones that give a count, is one of 6 that started in 2021, is one of 62 in phase 3, and was the 97th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
2 of the studies testing elexacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This study was evaluate the effect of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) on glucose tolerance in CF participants, 12 years of age and older who are heterozygous for the F508del mutation and a minimal function mutation (F/MF genotypes), with abnormal glucose metabolism.
Key Inclusion Criteria:
Abnormal glucose tolerance determined by an OGTT as either:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ELX 200 mg /TEZ 100 mg /IVA 150 mg in the morning and IVA 150 mg in the evening.
Drug: ELX/TEZ/IVA · Drug: IVA
Drug pages: Elexacaftor · Tezacaftor · Ivacaftor
Fixed dose combination (FDC) tablets for oral administration.
Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor
Tablets for oral administration.
Also known as: VX-770, ivacaftor
Change From Baseline in 2-hour Blood Glucose Levels Following an OGTT to the Average of Week 36 and Week 48
Baseline 2-hour post-OGTT blood glucose level was defined as the average of valid pre-dose measurements at screening and Day 1. OGTT results were considered valid only when the participant was fasting for at least 8 hours.
Time frame: Baseline, Week 36 and 48
Percentage of Participants With Improvement in Dysglycemia Categorization at Week 48
Baseline dysglycemia category was defined as the most recent non-missing measurement before the first dose of study drug in the treatment period. Improvement in dysglycemia is a change from cystic fibrosis-related diabetes (CFRD) at baseline to impaired glucose tolerance (IGT)/normal glucose tolerance (NGT) at Week 48 OR change from IGT at baseline to NGT at Week 48. CFRD: 2-hour post-OGTT blood glucose level ≥200 mg/dL or fasting blood glucose level ≥126 mg/dL; IGT: 2-hour post-OGTT blood glucose level ≥140 to \<200 mg/dL and fasting blood glucose level \<126 mg/dL; NGT: 2 hour post-OGTT blood glucose level \<140 mg/dL and fasting blood glucose level \<126 mg/dL.
Time frame: Baseline, Week 48
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 52
| Milestone | ELX/TEZ/IVA |
|---|---|
| Started | 69 |
| Completed | 66 |
| Not completed | 3 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal of consent (not due to ae) | 2 |
Baseline 2-hour post-OGTT blood glucose level was defined as the average of valid pre-dose measurements at screening and Day 1. OGTT results were considered valid only when the participant was fasting for at least 8 hours.
| milligrams per deciliter (mg/dl) | ELX/TEZ/IVA |
|---|---|
| Change From Baseline in 2-hour Blood Glucose Levels Following an OGTT to the Average of Week 36 and Week 48 | -35.0 (-49.2 to -20.7) |
Baseline dysglycemia category was defined as the most recent non-missing measurement before the first dose of study drug in the treatment period. Improvement in dysglycemia is a change from cystic fibrosis-related diabetes (CFRD) at baseline to impaired glucose tolerance (IGT)/normal glucose tolerance (NGT) at Week 48 OR change from IGT at baseline to NGT at Week 48. CFRD: 2-hour post-OGTT blood glucose level ≥200 mg/dL or fasting blood glucose level ≥126 mg/dL; IGT: 2-hour post-OGTT blood glucose level ≥140 to \<200 mg/dL and fasting blood glucose level \<126 mg/dL; NGT: 2 hour post-OGTT blood glucose level \<140 mg/dL and fasting blood glucose level \<126 mg/dL.
| percentage of participants | ELX/TEZ/IVA |
|---|---|
| Percentage of Participants With Improvement in Dysglycemia Categorization at Week 48 | 37.7 (24.8 to 52.1) |
| Participants | ELX/TEZ/IVA |
|---|---|
| Participants with TEAEs | 67 |
| Participants with SAEs | 6 |
Collected over Day 1 up to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ELX/TEZ/IVA | 0/69 (0%) | 6/69 (8.7%) | 62/69 (89.9%) |
| Event | ELX/TEZ/IVA |
|---|---|
| GastritisGastrointestinal disorders | 1/69 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 1/69 |
| InfluenzaInfections and infestations | 1/69 |
| SinusitisInfections and infestations | 1/69 |
| Clavicle fractureInjury, poisoning and procedural complications | 1/69 |
| HeadacheNervous system disorders | 1/69 |
| Heavy menstrual bleedingReproductive system and breast disorders | 1/69 |
| Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders | 1/69 |
| Event | ELX/TEZ/IVA |
|---|---|
| COVID-19Infections and infestations | 22/69 |
| PyrexiaGeneral disorders | 16/69 |
| HeadacheNervous system disorders | 16/69 |
| NasopharyngitisInfections and infestations | 15/69 |
| DiarrhoeaGastrointestinal disorders | 13/69 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 12/69 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/69 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 10/69 |
| Abdominal painGastrointestinal disorders | 9/69 |
| Abdominal pain upperGastrointestinal disorders | 8/69 |
All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis.
| Age, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| Less than (<)18 years | 19 |
| More than or equal to (≥)18 years | 50 |
| Sex: Female, Male(Participants) | ELX/TEZ/IVA |
|---|---|
| Female | 31 |
| Male | 38 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| Hispanic or Latino | 8 |
| Not Hispanic or Latino | 41 |
| Not collected per local regulations | 20 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| White | 48 |
| Black or African American | 0 |
| Asian | 0 |
| American Indian or Alaska Native | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Other | 1 |
| Not collected per local regulations | 20 |
| 2-hour Post-OGTT Blood Glucose Levels(milligrams per deciliter (mg/dl)) | ELX/TEZ/IVA |
|---|---|
| Mean | 217.6 ± 73.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Ran from Jan 2021 to primary completion in Jul 2022, 17 months.
Results were first posted in Aug 2023, 1 year after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 17 months is below that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →